AMLX
Amylyx Pharmaceuticals, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C+
Company Profile
CEO
Joshua Cohen
IPO Date
2022-01-07
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Amylyx Pharmaceuticals, Inc.
CEO
Joshua Cohen
IPO Date
2022-01-07
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 15,000 |
| $17.61 |
| 8 Jun 2026 | Zeiher Bernhardt G | director | A-Award | Acquired | 24,372 | $14.31 |
| 8 Jun 2026 | Firestone Karen | director | A-Award | Acquired | 24,372 | $14.31 |
| 8 Jun 2026 | Quimi Daphne | director | A-Award | Acquired | 24,372 | $14.31 |
| 8 Jun 2026 | MILNE GEORGE M JR | director | A-Award | Acquired | 24,372 | $14.31 |
| 8 Jun 2026 | FONTEYNE PAUL R. | director | A-Award | Acquired | 24,372 | $14.31 |
| 26 May 2026 | Firestone Karen | director | P-Purchase | Acquired | 3,800 | $13.51 |
| 9 Mar 2026 | Cohen Joshua B | director, officer: Co-Chief Executive Officer | A-Award | Acquired | 248,865 | $0.00 |
| 9 Mar 2026 | Cohen Joshua B | director, officer: Co-Chief Executive Officer | A-Award | Acquired | 373,295 | $14.10 |